{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:17:25Z","timestamp":1790057845416,"version":"4.0.1"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>To characterize demographic, clinical, and histopathologic features of ocular adnexal lymphoma (OAL) at a single institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Retrospective review of all patients with pathologic diagnosis of OAL between 2015 and 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      There were 133 patients with OAL, with a median age of 65 years (range 23\u201397) and a slight female predominance (male: female = 1:1.46), (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 79, 59%). The majority of tumors were non-Hodgkin B-cell lymphomas (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 131, 99%), most frequently Extranodal Marginal Zone B-Cell Lymphoma (EMZL,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 93, 70%), followed by follicular lymphoma (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 21, 16%), chronic lymphocytic leukemia\/small lymphocytic lymphoma (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 7, 5%), diffuse large B-cell lymphoma (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5, 4%), and mantle cell lymphoma (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5, 4%). The most frequently involved sites included the orbit (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 85, 64%) and conjunctiva (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 43, 32%). Information was available on oncologic staging in 78 (59%), treatment in 82 (62%), and follow-up in 75 (56%) patients. By the Ann-Arbor classification system, patients were classified as IE (54\/78, 69%), IIE (9\/78, 12%), IIIE (6\/78, 8%), and IVE (9\/78, 12%). The most common treatments included external beam radiotherapy (standard and ultra-low-dose) (48\/82, 59%), biologics (22\/82, 27%), and surgical excision with cryotherapy (14\/82, 17%) (some patients had &gt;1 therapy). Median follow-up time was 24 months (range 0\u2013221 months). Recurrence was observed in 13% (10\/75) with a median time to recurrence of 60 months (95% confidence interval 47\u201373 months). Excision with cryotherapy as a sole treatment modality was associated with earlier recurrence (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>In this largest single-center study of OAL, we found that most OAL were Ann-Arbor Stage IE EMZL, occurring in older patients with a female predominance. Early recurrence was noted in tumors treated with excision and cryotherapy alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/1319-4534.343368","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T03:25:36Z","timestamp":1653449136000},"page":"230-238","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Ocular adnexal lymphoma"],"prefix":"10.4103","volume":"35","author":[{"given":"C\u00e9sar A.","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger K.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurij R.","family":"Bilyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph C.","family":"Eagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Milman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-13-20240830","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/sj.leu.2404782","article-title":"MALT lymphoma in patients with autoimmune diseases: A comparative analysis of characteristics and clinical course","volume":"21","author":"W\u00f6hrer","year":"2007","journal-title":"Leukemia"},{"key":"R3-13-20240830","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1634\/theoncologist.2012-0425","article-title":"A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma","volume":"18","author":"Ponzoni","year":"2013","journal-title":"Oncologist"},{"key":"R4-13-20240830","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/eye.2012.247","article-title":"Molecular pathology of lymphoma","volume":"27","author":"Coupland","year":"2013","journal-title":"Eye (Lond"},{"key":"R5-13-20240830","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1526-9655(11)70005-7","article-title":"Primary intraocular lymphoma: Clinical features, diagnosis, and treatment","volume":"4","author":"Chan","year":"2003","journal-title":"Clin Lymphoma"},{"key":"R6-13-20240830","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1442-9071.2008.01843.x","article-title":"Understanding intraocular lymphomas","volume":"36","author":"Coupland","year":"2008","journal-title":"Clin Exp Ophthalmol"},{"key":"R7-13-20240830","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1076\/ocii.12.1.7.28072","article-title":"Diagnosis of intraocular lymphoma","volume":"12","author":"Davis","year":"2004","journal-title":"Ocul Immunol Inflamm"},{"key":"R8-13-20240830","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/1097-0142(19940501)73:9<2395::AID-CNCR2820730924>3.0.CO;2-V","article-title":"Orbital and adnexal involvement in systemic non-Hodgkin's lymphoma","volume":"73","author":"Bairey","year":"1994","journal-title":"Cancer"},{"key":"R9-13-20240830","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1586\/eop.11.16","article-title":"Descriptive epidemiology of ophthalmic and ocular adnexal non-Hodgkin's lymphoma","volume":"6","author":"Moslehi","year":"2011","journal-title":"Expert Rev Ophthalmol"},{"key":"R10-13-20240830","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ophtha.2003.01.002","article-title":"Survey of 1264 patients with orbital tumors and simulating lesions: The 2002 Montgomery Lecture, part 1","volume":"111","author":"Shields","year":"2004","journal-title":"Ophthalmology"},{"key":"R11-13-20240830","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.ophtha.2008.02.004","article-title":"Orbital lymphoproliferative tumors: Analysis of clinical features and systemic involvement in 160 cases","volume":"115","author":"Demirci","year":"2008","journal-title":"Ophthalmology"},{"key":"R12-13-20240830","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0161-6420(95)30764-6","article-title":"Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type","volume":"102","author":"White","year":"1995","journal-title":"Ophthalmology"},{"key":"R13-13-20240830","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0161-6420(98)98024-1","article-title":"Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases","volume":"105","author":"Coupland","year":"1998","journal-title":"Ophthalmology"},{"key":"R14-13-20240830","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0046-8177(90)90181-4","article-title":"Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): A prospective multiparametric analysis of 108 cases during 1977 to 1987","volume":"21","author":"Knowles","year":"1990","journal-title":"Hum Pathol"},{"key":"R15-13-20240830","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.survophthal.2016.04.004","article-title":"Lymphoid hyperplasia of the orbit and ocular adnexa: A clinical pathologic review","volume":"61","author":"Andrew","year":"2016","journal-title":"Surv Ophthalmol"},{"key":"R16-13-20240830","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0161-6420(01)00932-0","article-title":"Orbital tumors in the older adult population","volume":"109","author":"Demirci","year":"2002","journal-title":"Ophthalmology"},{"key":"R17-13-20240830","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2008-12-195453","article-title":"Extranodal marginal zone lymphoma of the ocular adnexa","volume":"114","author":"Stefanovic","year":"2009","journal-title":"Blood"},{"key":"R18-13-20240830","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/modpathol.3880366","article-title":"Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: Characterization of malt lymphoma and reactive lymphoid hyperplasia","volume":"14","author":"Mannami","year":"2001","journal-title":"Mod Pathol"},{"key":"R19-13-20240830","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdm513","article-title":"Ocular adnexal MALT lymphoma: An intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy","volume":"19","author":"Ferreri","year":"2008","journal-title":"Ann Oncol"},{"key":"R20-13-20240830","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/bjo.85.1.63","article-title":"Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma","volume":"85","author":"Auw-Haedrich","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"R21-13-20240830","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1023\/A:1008327301372","article-title":"Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa","volume":"9","author":"Baldini","year":"1998","journal-title":"Ann Oncol"},{"key":"R23-13-20240830","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"R24-13-20240830","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3322\/canjclin.47.6.351","article-title":"Non-Hodgkin's lymphomas: Current classification and management","volume":"47","author":"Skarin","year":"1997","journal-title":"CA Cancer J Clin"},{"key":"R25-13-20240830","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R26-13-20240830","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00002341-199903000-00012","article-title":"Low-dose radiotherapy for lymphoid lesions of the orbit and ocular adnexa","volume":"15","author":"Kennerdell","year":"1999","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R27-13-20240830","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.23638","article-title":"Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the Surveillance, Epidemiology and End Results database","volume":"89","author":"Castillo","year":"2014","journal-title":"Am J Hematol"},{"key":"R29-13-20240830","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/01.pas.0000213350.49767.46","article-title":"Lymphoma of the ocular adnexa: A study of 353 cases","volume":"31","author":"Ferry","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R30-13-20240830","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.sjopt.2013.07.003","article-title":"Ocular adnexal lymphoproliferative disorders in an ophthalmic referral center in Saudi Arabia","volume":"27","author":"Alkatan","year":"2013","journal-title":"Saudi J Ophthalmol"},{"key":"R31-13-20240830","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5301\/ejo.5000224","article-title":"Ocular adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor","volume":"23","author":"Graue","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"R32-13-20240830","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ophtha.2017.05.037","article-title":"Treatments for ocular adnexal lymphoma: A report by the American academy of ophthalmology","volume":"125","author":"Yen","year":"2018","journal-title":"Ophthalmology"},{"key":"R33-13-20240830","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.20137","article-title":"Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma","volume":"77","author":"Nola","year":"2004","journal-title":"Am J Hematol"},{"key":"R34-13-20240830","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.survophthal.2018.08.002","article-title":"Orbital lymphoma","volume":"64","author":"Olsen","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"R35-13-20240830","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/IOP.0000000000000789","article-title":"Rates of positive findings on positron emission tomography and bone marrow biopsy in patients with ocular adnexal lymphoma","volume":"33","author":"Thuro","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R36-13-20240830","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/cncr.11539","article-title":"Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: A multiinstitutional, retrospective review of 50 patients","volume":"98","author":"Uno","year":"2003","journal-title":"Cancer"},{"key":"R37-13-20240830","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdj025","article-title":"Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma","volume":"17","author":"Tanimoto","year":"2006","journal-title":"Ann Oncol"},{"key":"R38-13-20240830","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0360-3016(98)00535-5","article-title":"Radiotherapy in the management of orbital lymphoma","volume":"44","author":"Bolek","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R39-13-20240830","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0360-3016(01)02729-8","article-title":"Primary radiotherapy for localized orbital MALT lymphoma","volume":"52","author":"Le","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R40-13-20240830","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1076\/orbi.21.2.117.7192","article-title":"Results of radiotherapy for orbital and adnexal lymphoma","volume":"21","author":"Liao","year":"2002","journal-title":"Orbit"},{"key":"R41-13-20240830","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0360-3016(03)00506-6","article-title":"Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification","volume":"57","author":"Hasegawa","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R42-13-20240830","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: Field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R43-13-20240830","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/hed.24717","article-title":"Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma","volume":"39","author":"Pinnix","year":"2017","journal-title":"Head Neck"},{"key":"R44-13-20240830","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R45-13-20240830","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: Ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"R46-13-20240830","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3109\/02713683.2014.959605","article-title":"Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: Single institution experience","volume":"40","author":"Tuncer","year":"2015","journal-title":"Curr Eye Res"},{"key":"R47-13-20240830","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/10428190310001641233","article-title":"Somatostatin receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with rituximab","volume":"45","author":"Morgensztern","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"R48-13-20240830","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-0609.2004.00299.x","article-title":"Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva","volume":"73","author":"N\u00fcckel","year":"2004","journal-title":"Eur J Haematol"},{"key":"R49-13-20240830","first-page":"1578","article-title":"Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa","volume":"90","author":"Ferreri","year":"2005","journal-title":"Haematologica"},{"key":"R50-13-20240830","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00277-006-0134-0","article-title":"Rituximab as first line treatment for MALT lymphoma of extraocular muscles","volume":"85","author":"Benetatos","year":"2006","journal-title":"Ann Hematol"},{"key":"R51-13-20240830","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/bjo.2007.115626","article-title":"Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland","volume":"91","author":"Heinz","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R52-13-20240830","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"R53-13-20240830","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000074641","article-title":"Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma","volume":"65","author":"Raderer","year":"2003","journal-title":"Oncology"},{"key":"R54-13-20240830","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428190701457949","article-title":"Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma","volume":"48","author":"Lossos","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R55-13-20240830","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bjh.12573","article-title":"Bruton tyrosine kinase inhibitors: A promising novel targeted treatment for B cell lymphomas","volume":"163","author":"Aalipour","year":"2013","journal-title":"Br J Haematol"},{"key":"R56-13-20240830","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study","volume":"31","author":"Zucca","year":"2013","journal-title":"J Clin Oncol"},{"key":"R57-13-20240830","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2005.05943.x","article-title":"Absence of Chlamydia psittaci in ocular adnexal lymphoma from Japanese patients","volume":"132","author":"Daibata","year":"2006","journal-title":"Br J Haematol"},{"key":"R58-13-20240830","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3928\/15428877-20070701-08","article-title":"Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy","volume":"38","author":"Gayed","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"}],"container-title":["Saudi Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/1319-4534.343368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:09:56Z","timestamp":1787166596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1319-4534.343368"}},"subtitle":["A single-institution retrospective study"],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/1319-4534.343368","relation":{},"ISSN":["1319-4534"],"issn-type":[{"value":"1319-4534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}